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The aim of the present study was to develop the PLGA/HP55 nanoparticles with improved hypoglycemic effect for
oral insulin delivery. The insulin-loaded PLGA/HP55 nanoparticles were produced by a modified multiple emulsion
solvent evaporation method. The physicochemical characteristics, in vitro release of insulin, and in vivo efficacy in
diabetic rats of the nanoparticles were evaluated. The insulin encapsulation efficiency was up to 94%, and insulin
was released in a pH-dependent manner under simulated gastrointestinal conditions. When administered orally
(50 IU/kg) to diabetic rats, the nanoparticles can decrease rapidly the blood glucose level with a maximal effect
between 1 and 8 h. The relative bioavailability compared with subcutaneous injection (5 IU/kg) in diabetic rats was
11.3%± 1.05%. This effect may be explained by the fast release of insulin in the upper intestine, where it is better
absorbed by the high gradient concentration of insulin than other regions. These results show that the PLGA/HP55
nanoparticles developed in the study might be employed as a potential method for oral insulin delivery.
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Insulin is the most effective medicine in lowering the
glucose level of blood for the treatment of diabetes mel-
litus [1]. Early introduction of insulin can also protect is-
lets from apoptosis and increase β-cell regeneration in
type 2 diabetes [2]. Subcutaneous injections of insulin
remain to be the preferred approach for diabetic patients
but often result in poor patient compliance [3,4]. Oral
administration of insulin seems to be the most conveni-
ent way and can mimic endogenous production of insu-
lin [5]. However, a reliable insulin formulation for the
oral delivery is encountered with some barriers in the
gastrointestinal (GI) tract that include (a) enzymatic deg-
radation in the GI tract and (b) poor insulin permeability
through the GI system [6]. The bioavailability of insulin
solution delivered orally is less than 1% [7].
pH-sensitive polymers have been developed and intro-
duced into the particulate carriers to circumvent the
barriers for oral insulin delivery. As early as 1999, insulin
was formulated with pH-sensitive microparticles, and a
prolonged reduction of hyperglycemia was observed* Correspondence: celjzh@scut.edu.cn
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in any medium, provided the original work is pafter oral administration to diabetic rats [7]. This reduc-
tion was dose dependent and lasted up to 8 h with a
dose of 25 IU/kg of encapsulated insulin. These results
were confirmed by pH-responsive hydrogel particles and
demonstrated a similar manner in the reduction of
blood glucose level after oral administration of poly-
meric dosage form and direct injection of insulin [8,9].
Generally, nanoparticles have greater intracellular uptake
compared with microparticles and are available to a
greater range of biologic targets due to their smaller size
and mobility [10]. Depending on the pH-sensitive poly-
mer combinations, nanoparticles can be tailored to con-
trol release kinetics, facilitate the uptake of insulin, and
increase the oral bioavailability [11,12]. Various pH-
sensitive nanoparticles based on pH-sensitive polymers
were developed for oral delivery of insulin. These pH-
sensitive polymers include polymethacrylic acid [13-
18], hydroxypropyl methylcellulose phthalate (HPMCP
(HP55)) [19], dextran sulphate [20-23], alginate [21,24],
poly-γ-glutamic acid [25,26], and so on. Generally, these
formulations prepared with these pH-sensitive polymers,
orally administered mostly to diabetic rats, induced a dif-
ferent extent reduction in blood glucose level.
However, absorption of insulin from different regions
of the intestine is not uniform due to the cellularpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Wu et al. Nanoscale Research Letters 2012, 7:299 Page 2 of 8
http://www.nanoscalereslett.com/content/7/1/299morphology of the intestines’ changes from region
to region [23,27-29]. Interestingly, the plasma insulin
concentration-time curves after orally delivered nano-
particles showed different insulin peaks. According to
the time of insulin peaks, the ways of insulin absorp-
tion could be divided into the fast and the slow ab-
sorption way (the dividing point is often observed in 8 h
of post-administration). The fast absorption way is prob-
ably related to insulin directly absorbed through para-
cellular pathway [23,24,28,30]. The slow absorption way
is possibly related to higher insulin residence time at
the absorption site and delay of nanoparticle uptake by
endocytosis via enterocytes or M cells in the small intes-
tine [23,24,29]. Insulin within carrier could be directly
absorbed through the intestinal wall exerting a hypo-
glycemic effect [31,32]. Insulin level in blood after intra-
duodenal injection of insulin/carrier solution showed the
insulin peak occurred in 20 to 40 min [33,34]. The
upper intestinal area seems to be the most active region
for insulin absorption [35]. In addition, nanoparticles or-
ally delivered are an aqueous suspension; they will leave
the stomach of fasted animals very rapidly and arrive in
the upper intestine where they will be able to release
insulin [28]. Hence, the nanoencapsulated insulin rapidly
absorbed may occur primarily in the upper intestine.
We hypothesized that the insulin, remaining high con-
centration due to the fast release from the pH-sensitive
nanoparticles with high entrapment efficiency, should be
better absorbed by the upper intestinal mucosa and, in
consequence, should rapidly produce the biological effi-
cacy. In addition, the rapid adsorption of insulin in the
upper intestine would decrease the loss of drug across
the intestine. Thus, the present study aims to develop an
oral dosage of insulin-loaded nanoparticles composed of
poly (lactide-co-glycolide (PLGA)/HP55 with strong drug
encapsulation ability and good pH-sensitive release prop-
erty. The nanoparticles were prepared by a novel tech-
nique of modified multiple emulsion solvent evaporation
(MESE) method. The physicochemical characterization
(morphology, size, insulin loading, and in vitro release of
insulin) of nanoparticles was examined and evaluated.
The biological efficacy after oral administration of insu-




Pure crystalline porcine insulin was purchased from
Xuzhou Wanbang Bio-Chemical Co. Ltd., (No. 0312A02,
Jiangsu, China), with a nominal activity of 27 IU/mg.
PLGA (50/50, Mw is about 20,000) was acquired from
Shandong Medical Instrument Institute (Shandong,
China). The HPMCP (HP55, Mw is about 45,000) and
polyvinyl alcohol (87% hydrolysed, Mw is about 31,000to 50,000) were purchased from Acros Organics (NJ,
USA). All other reagents and solvents used were analyt-
ical grade. Streptozotocin (STZ; HPLC) was purchased
from Sigma-Aldrich, Corporation, St. Louis, MO, USA.
Distilled and deionized water (Mili-Q water systems,
Millipore, Bedford, MA, USA) was used for the prepar-
ation of all sample solutions.
Animals
Male sprague Dawley rats weighing 220 to 250 g, 12 to
13 weeks old, were provided by the pharmacological la-
boratory of the Hong Kong University of Science and
Technology. They received standard laboratory chow
diet and tap water, available ad libitum. All experiments
were carried out in accordance with the Guideline for
the Care and Use of Experiment Animals in Hong Kong
University of Science and Technology, Hong Kong.
Preparation of insulin-loaded PLGA/HP55 nanoparticles
The preparation of nanoparticles was carried out by the
modified MESE technique. Briefly, the inner aqueous
phase of pH 2.0 insulin solution (10 mg/mL, 1 mL) was
added into the oil phase of polymer solution (PLGA/
HP55, 50 mg/100 mg) using methylene chloride and
acetone (3 mL/2 mL) and then the resulting mixture
was emulsified to form the primary emulsion by sonifi-
cation at power of 40 W for 0.5 min (SONOPULS, Ban-
delin, German). The primary emulsion was thereafter
poured into 20 mL of external aqueous phase of polyvi-
nyl alcohol solution (1%, w/v) and sonicated at power of
60 W for 1 min, involving the formation of the multiple
emulsions. After evaporation of solvents under reduced
pressure, the nanoparticles were collected by centrifuga-
tion at 20,000 rpm for 10 min and then washed three
times with distilled water. The insulin-loaded PLGA/
HP55 nanoparticles were vacuum freeze-dried for 24 h
after prefreezing of the resultant dispersion at −20°C
overnight.
Characterization of nanoparticles
The size of nanoparticles was determined by photon cor-
relation spectroscopy at 25°C with a detection angle of
90° using a Malvern Zetasizer II (Malvern Instruments
Ltd., Worcestershire, UK). Measurements were made on
aqueous dilute nanoparticle suspension.
The morphology of nanoparticles was determined by
scanning electron microscopy (SEM) (LEO 1530 VP, LEO
Elektronenmikroskopie GmbH, Oberkochen, Germany)
and transmission electron microscopy (TEM) (Hitachi
JEM-100 CXII, Hitachi Ltd., Chiyoda, Tokyo, Japan).
For SEM measurement, the powder of nanoparticles
was fixed on an aluminum stub as a thin film and coated
with gold before observation. SEM was performed at an
accelerating voltage of 10 kV and a magnification
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measurement, an aqueous droplet of nanoparticle solu-
tions was immobilized on copper grids and negatively
stained with phosphotungstate solution (2%, w/v). After
drying at room temperature, the morphology of the
nanoparticles was examined.
The drug encapsulation efficiency (EE) and loading
capacity (LC) were calculated by the following formulas
[36]:









where Mtotal is initial amount of insulin (mg); Vsupernatant,
volume of supernatant (mL); Csupernatant, concentration
of insulin in supernatant (mg/mL); and Wnanoparticle,
weight of nanoparticles.
The concentration of insulin was determined by re-
verse phase HPLC method (Agilent 1200, ZORBAX 300
SB-C18 column 150 mm×4.6 mm, 5 μm, Agilent Tech-
nologies Inc., Santa Clara, CA, USA).[37] The mobile
phase consisted of a premixed isocratic mixture of 0.2 M
sodium sulfate anhydrous solution adjusted to pH 2.3
with phosphoric acid and acetonitrile (73:27, v/v). The
injection volume for samples and standards were 20 μL
and eluted at a flow rate of 0.8 mL min−1 at 30°C. The
absorbance of insulin was determined using the UV
trace at 214 nm.
In vitro release study
Five milligrams of the insulin-loaded nanoparticles were
dispersed in 5-mL simulated gastric fluid (pH 1.2) and
simulated intestinal fluid (pH 7.4), respectively, and
shaken at 50 rpm at 37.8°C using a constant-temperature
shaker (SHA-B, Guohua Co. Ltd., Jiangsu, China). At
specified time intervals (0, 30, 60, 120, 180, 240, and
480 min), supernatants were collected by centrifugation.
The concentrations of insulin in the supernatant were
determined by reverse phase HPLC method, and total
amount of insulin released from the nanoparticles was
calculated. Each experiment was carried out in triplicate.
In vivo study in diabetic rats
Male sprague Dawley rats were made diabetic prior to
the study by intravenous injection of 60-mg/kg STZ dis-
solved in citrate buffer at pH 4.5. They were considered
to be diabetic when the fasted glucose levels exceeded
250 mg/dL 2 weeks after STZ treatment. The rats werethen used to evaluate the hypoglycemic effects of the in-
sulin-loaded PLGA/HP55 nanoparticles.
Diabetic rats were fasted for 12 h prior to and
remained fasted during the experiment but were allowed
free access to water throughout the whole experiment.
Blood samples were collected from the tail veins of rats
prior to drug administration and at different time inter-
vals after dosing. The blood glucose was then deter-
mined by a glucose meter using ACCU-Chek Active
(Roche Diagnostics, Mannheim, Germany).
Hypoglycemic effect was evaluated by the decrease of
plasma glucose levels relative to the basal values in rats
divided in three groups (n= 3/group) corresponding to
(a) subcutaneous (SC)-injected free-form insulin at dose
of 5 IU/kg and (b) orally delivered insulin-loaded nano-
particles and (c) orally delivered blank nanoparticles.
Plasma insulin levels were determined by a solid two-
side enzyme immunoassay (ELISA test kit, Mercodia,
Uppsala, Sweden) based on the direct sandwich tech-
nique in which two monoclonal antibodies are directed
against separate antigenic determinants on the inulin
molecule. The plasma were separated by centrifugation
(3,000 rpm, 4°C, 20 min) and samples were stored at 2°C
to 8°C, then 25μL of sample added to each well of a 96-
well microplate using the assay’s protocol. The insulin
concentration was quantified against a standard curved
using absorbance at 450 nm (Wallac VICTOR plate
reader 1420, Perkin Elmer, Waltham, MA, USA). Plasma
insulin levels were plotted against time to evaluate the
relative bioavailability. The relative bioavailability (BAR)
was obtained according to formula (3).
BAR %ð Þ ¼ AUCoral  DoseSCAUCSC  Doseoral  100 %; ð3Þ
where AUCoral is the total area under the serum insulin
concentration vs. time curve of oral administration of in-
sulin nanoparticles; AUCSC, total area under the serum
insulin concentration vs. time curve of pure insulin in-
jection; DoseSC, dosage of pure insulin injection (IU/kg);
and Doseoral, dosage of oral administration of insulin
nanoparticles (IU/kg).
Statistical analysis
Data are presented as mean± standard deviation (S.D.).
Comparison between two groups was analyzed by the
one-tailed Student’s t-test. A statistical difference was
considered when p value was less than 0.05.
Results and discussion
Preparation and characterization of insulin-loaded PLGA/
HP55 nanoparticles
Polymeric nanoparticles based on the HP55 could not
be produced by the traditional multiple emulsion solvent
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in a solvent (such as methylene chloride or ethyl acet-
ate), which can easily be removed by evaporation or
by the other extraction. In general, the hydrophilic
molecules such as insulin can be encapsulated in
water-containing emulsion. Although the PLGA/HP55
nanoparticles were prepared by single emulsion solv-
ent diffusion (SESD) method in the literature, using
the acetone/water as the solvent, the encapsulation effi-
ciency as well as pH-sensitivity is poor [19]. These prop-
erties in PLGA/HP55 nanoparticles could significantly
contribute to the low absorption of insulin in the intes-
tine. As shown in Figure 1, novel insulin-loaded PLGA/
HP55 nanoparticles were developed by the modified
MESE method. When the methylene chloride was mixed
with the acetone, the resultant solvent mixture could
dissolve the blend polymers of PLGA and HP55 used to
prepare multiple emulsions. The condition of pH 2.0
was used in the preparation of insulin-loaded nanoparti-
cles in order to increase the dissolubility of insulin. The
activities of insulin were not reduced much due to
the short time of the preparation process. In addition,
the nanoparticles were washed three times with DI
water and dried, which may also reduce the effect of
acid condition on the activities of insulin. These can
also be verified by the in vivo results followed.
Figure 2a shows that insulin solution as the inner
aqueous phase could be protected by the oil phase
through formation of multiple emulsions. In addition,
the improvement of the multiple emulsions may have
the chance to uniformly distribute the insulin in the
polymer matrix. HP55 phase could firstly be phase sepa-
rated from the polymer solution in the oil phase after
formation of the multiple emulsions, which attribute to
the diffusion of acetone from the primary emulsion to
the external aqueous solution (Figure 2b). Insulin dro-
plets tend to be distributed in the HP55 matrix via the
strong interaction between the carboxylic groups in
phthalate groups of HP55 and amide groups in insulin
[19]. The formation of PLGA/HP55 nanoparticles oc-
curred after the evaporation of methylene chloride
(Figure 2c). The physical stability of PLGA/HP55Figure 1 Scheme of the preparation of insulin-loaded PLGA/HP55 nannanoparticles will be smartly increased in the acidic en-
vironment due to the hydrophobic protection of PLGA
and HP55. Hence, the burst release of insulin from
PLGA/HP55 nanoparticles in acidic environment would
be reduced using the multiple emulsion solvent evapor-
ation method.
The morphologies of PLGA/HP55 nanoparticles by
SEM and TEM analyses are shown in Figure 3. The
nanoparticles possess a spherical shape and uniform size.
The particle sizes of the nanoparticles are listed in
Table 1. The results showed that the number of average
particle size of the PLGA/HP55 nanoparticles prepared
by MESE method was 181.9 ± 19.0 nm (PDI = 0.093 ±
0.031), a little larger than 169 ± 16 nm of PLGA/HP55
nanoparticles prepared by SESD method [19]. In general,
the nanoparticles formulated from multiple emulsions
were much larger in size than that obtained from simple
emulsions [38].
Drug entrapment ability of PLGA/HP55 nanoparticles
The drug entrapment ability of PLGA/HP55 nanoparti-
cles prepared by SESD and MESE techniques is com-
pared in Table 1. Entrapment efficiency (EE) was
significantly dependent on the preparation method [39].
The reason for this lower EE (65.41% ± 2.3%) by SESD is
due to the low affinity between the polymer and hydro-
philic drug, leading to the drug substance tendency to
move from the organic phase to the outer aqueous phase
during the single emulsion diffusion process. In order to
avoid this, the hydrophilic insulin partitioned between
the two immiscible phases (the inner aqueous phase and
the oil phase), allowing the drug to be initially dissolved
in an inner aqueous phase. Hence, the high EE
(94.25%± 1.24%) was obtained by MESE technique in
the study.
The novel MESE preparation technique described here
for the encapsulation of hydrophilic macromolecule in
PLGA/HP55 nanoparticles resulted in improved encap-
sulation efficiency in comparison to the SESD technique.
Obviously, the success of this technique hinges upon
the ability to construct biocompatible nanoparticles
that allow high loading of insulin molecules withoutoparticles.
Figure 2 Phase separation in multiple emulsions. Includes (a) formation of multiple emulsions, (b) acetone solvent diffusion and formation of
HP55 phase, and (c) methylene chloride evaporation and formation of PLGA/HP55 nanoparticles.
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intestine.
In vitro release profiles from insulin-loaded PLGA/HP55
nanoparticles
In vitro insulin releases of the nanoparticles were per-
formed respectively under gastric environment (pH 1.2)
and intestinal conditions (pH 7.4), and the results are
shown in Figure 4. For the nanoparticles prepared with
pH-sensitive polymer HP55, the release rate of insulin
from the nanoparticles is markedly influenced by pH
values. At pH 1.2, less than 15% insulin could be
released, while at a higher pH value of 7.4, about 90% in-
sulin could be released from the nanoparticles. The sen-
sitivity of insulin release towards pH could mainly
depend on the solubility of HP55. At pH 1.2, HP55 and
PLGA molecules are hydrophobic ones which couldFigure 3 Morphology of insulin-loaded PLGA/HP55
nanoparticles.reduce the contact of water and insulin molecules and
prevent the release of insulin molecules from the nano-
particles. At pH 7.4, HP55 can dissolve in water, facilitat-
ing the release of insulin molecules which mainly
distribute in the PLGA/HP55 matrix. The PLGA
increases the matrix stability, avoiding the rapid disinte-
gration of nanoparticles, due to its indissolubility in
water. Such pH-sensitive release property would be fa-
vorable for the protection of orally delivered insulin
when nanoparticles passed through the acid environ-
ment of the stomach [7,16].
Oral administration of insulin-loaded PLGA/HP55
nanoparticles in diabetic rats
The pharmacological effect of insulin-loaded PLGA/
HP55 nanoparticles was evaluated in diabetic rats dosed
orally at loading level of 50 IU/kg; the number of ani-
mals per group is three. The changes in plasma glucose
compared to insulin injected subcutaneously at 5 IU/kg
and blank nanoparticles dosed orally are shown in
Figure 5. A significant difference in plasma glucose
reduction between insulin-loaded and blank nanopar-
ticles was observed, especially 1 to 8 h after oral ad-
ministration (p< 0.05).
Oral administration of the insulin-loaded PLGA/HP55
nanoparticles and SC injection of the free-form insulin
solution produced a significant hypoglycemic effect,Table 1 Properties of insulin-loaded PLGA/HP55
nanoparticles prepared via MESE and SESD methods
(mean± S.D., n=3)
Particle size (nm) EE (%) LC (%)
SESDa 169± 16 65.41 ± 2.3 3.17 ± 0.24
MESE 181.9 ± 19.0 94.25 ± 1.24 5.89 ± 0.17
aThe data are provided by literature [19]. EE, encapsulation efficiency; LC,
loading capacity.
Figure 4 In vitro release profiles of insulin-loaded PLGA/HP55
nanoparticles (mean± S.D., n=3).
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cesses did not lead to the fragmentation of insulin mole-
cules. SC injection of the insulin solution produced a
sharp decrease in blood glucose levels (90% in 2 h),
which gradually returned to the basal levels after 8 h.
The fast and prolonged reduction in blood glucose levels
was investigated between 1 and 8 h after oral adminis-
tration of the nanoparticles. This phenomenon of fast re-
duction of blood glucose levels was also conformed
within 2 h after oral delivered aspart-insulin or insulin-
loaded nanoparticles, which could be attributed to the
initial release of insulin from the nanoparticles [24,28].
The quick pass of nanoparticle suspension through the
stomach of fasted rats also has the promoted effect on
the rapid reduction of blood glucose. The advantages of
the present pH-sensitive nanoparticles are the use of aFigure 5 Plasma glucose levels. After oral administration of the
insulin-loaded PLGA/HP55 nanoparticles (50 IU/kg), blank
nanoparticles, and SC injection of insulin solution (5.0 IU/kg) in
diabetic rats (mean± S.D., n= 3). Significant difference from blank
nanoparticles control (p< 0.05).multiple emulsion method increasing the drug entrap-
ment ability and addition of HP55 that greatly in-
crease pH-sensitivity of nanoparticles. Compared to the
nanoparticles developed by Cui et al. [19], showing simi-
lar PLGA/HP55-based nanoparticles, the present nano-
particles showed an improved entrapment ability by
increasing the encapsulation efficacy by 1.4-fold and
improved release property by increasing the release of
insulin from nanoparticles at pH= 7.4 within 1 h by 1.3-
fold. These improvements would promote the insulin
absorbed as a free peptide in the upper intestine either
by a paracellular pathway or a receptor-mediated
pathway.
Insulin could be directly absorbed through the intes-
tinal cell exerting a hypoglycemic effect [31,32]. The dir-
ect uptake of insulin has been attributed to specific
insulin receptors in intestinal enterocytes and rapid
internalization of the nanoparticles by the epithelial cells
[23,40,41]. The upper intestinal area seems to be the
most active region for insulin absorption, improved
under fasting conditions [35]. Hence, the fast reduction
of blood glucose level after oral insulin-loaded PLGA/
HP55 nanoparticles could be attributed to the fast re-
lease of insulin in the upper intestine, wherein the pH is
approximately 6.0 to 7.0 [42].
The intestinal absorption of nanoencapsulated insulin
was evaluated by measuring serum insulin levels in
diabetic rats. Corresponding plasma insulin concentration-
time profiles and the related pharmacokinetic parameters
are shown in Figure 6 and Table 2, respectively. As shown,
insulin levels increased 1 h after oral administration of
insulin-loaded PLGA/HP55 nanoparticles, and the one
insulin peak was observed at 3-h post-administration.
The initial burst seems to be of value regarding the
mechanism of absorption of insulin [28]. The only oneFigure 6 Serum insulin levels. After oral administration of insulin-
loaded PLGA/HP55 nanoparticles (50 IU/kg) and SC injection of
insulin solution (5.0 IU/kg) in diabetic rats (mean± S.D., n= 3).







Dose (IU/kg) 5.0 50
Cmax (μIU/mL) 129.21 ± 8.49 69.93 ± 7.64
Tmax (h) 0.33 3
AUC(0 to 8 h) (μIU h/mL) 143.76 ± 21.37 161.69 ± 28.58
BAR (%) 100 11.3 ± 1.05
Parameters after SC administration of the free-form insulin solution or oral
administration of insulin-loaded PLGA/HP55 nanoparticles. AUC, area under
the plasma concentration-time curve; BAR, relative bioavailability; Cmax,
maximum plasma concentration; Tmax, time at which Cmax is attained. Data are
given as mean± S.D. (n= 3).
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initially released from PLGA/HP55 nanoparticles allow-
ing a high drug gradient concentration directly absorbed
through the receptor-mediated pathway or paracellular
pathway [29,40,41]. The AUC (0 to 8 h) for the group
orally treated with the insulin-loaded PLGA/HP55 nano-
particles was 161.69± 28.58 μIU h/mL, which corre-
sponded to a bioavailability of 11.3%±1.05% showing
improved insulin absorption.
The bioavailability for insulin-loaded PLGA/HP55
nanoparticles obtained by the SESD technique is
6.27%± 0.42%. By introducing the MESE method into
the preparation of PLGA/HP55 nanoparticles, the
physiological effect was improved by increasing the bio-
availability by 1.8-fold. Compared with PLGA/HP55
nanoparticles prepared by SESD technique, the encapsu-
lated insulin by MESE technique can be released very
rapidly allowing a high drug gradient concentration in
the upper intestine followed by a good absorption.Conclusions
In this study, novel PLGA/HP55 nanoparticles with a
pH-sensitive characteristic were prepared by MESE tech-
nique for oral delivery of insulin. The PLGA/HP55
nanoparticles exhibited an excellent insulin entrapment
ability and a good pH-sensitive release behavior. Add-
itionally, the pharmacodynamic and pharmacokinetic
evaluations of orally administered PLGA/HP55 nanopar-
ticles in diabetic rats indicated that absorption of insulin
in the upper intestine was fast, and the hypoglycemic ef-
fect was significant. These results suggested that the
PLGA/HP55 nanoparticles developed in the study might
be employed as a potential approach for the multiple
daily oral delivery of insulin.Competing interests
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